Abstract
t(11; 18) (q21; q21) is a chromosomal aberration specific to low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, and generates the chimeric product apoptosis inhibitor 2 (API2)-MALT1, which has been suggested to play an important role in MALT lymphomagenesis. However, little is known about the characteristics of API2, MALT1, and API2-MALT1 proteins. We therefore investigated the subcellular localization and stability of these products. API2 was localized in the nucleus and the cytoplasm, and MALT1 and API2-MALT1 in the cytoplasm only. Western blot analysis showed that the products of API2 and MALT1 were unstable, while the API2-MALT1 product was stable. The API2 deletion mutants at the end of the C-terminal and the MALT1 deletion mutants at the end of the N-terminal were stable compared with the full-length products. These results indicate that the domains responsible for protein instability are located in the end of the C-terminal of API2 and in that of the N-terminal of MALT1, and also that API2-MALT1 became stable because it lacks these domains. It has been suggested that NF-κB activation plays an important role in the tumorigenesis of MALT lymphoma. Our findings further suggest that the stabilized expression of API2-MALT1 products may continuously stimulate the NF-κB activating pathway, thus leading to MALT lymphomagenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, Suzuki H, Ota H, Nakamura S, Morishima Y, Taniwaki M and Seto M . (1999). Oncogene, 18, 5785–5794.
Baens M, Maes B, Steyls A, Geboes K, Marynen P and Wolf-Peeters CD . (2000). Am. J. Pathol., 156, 1433–1439.
Barkett M and Gilmore TD . (1999). Oncogene, 18, 6910–6924.
Deveraux QL and Reed JC . (1999). Genes Dev., 13, 239–252.
Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, Wolf-Peeters CD, Hagemeijer A, Berghe HV and Marynen P . (1999). Blood, 93, 3601–3609.
Fang S, Jensen JP, Ludwig RL, Vousden KH and Weissman AM . (2000). J. Biol. Chem., 275, 8945–8951.
Hozak RR, Manji GA and Friesen PD . (2000). Mol. Cell. Biol., 20, 1877–1885.
Huang H, Joazeiro CAP, Bonfoco E, Kamada S, Leverson JD and Hunter T . (2000). J. Biol. Chem., 275, 26661–26664.
Inagaki H, Okabe M, Seto M, Nakamura S, Ueda R and Eimoto T . (2001). Am. J. Pathol., 158, 699–706.
Isaacson PG . (1999). Semin. Hematol., 36, 139–147.
Isaacson PG and Spencer J . (1987). Histopathology, 11, 445–462.
Kalla J, Stilgenbauer S, Schaffner C, Wolf S, Ott G, Greiner A, Rosenwald A, Dohner H, Muller-Hermelink HK and Lichter P . (2000). Leukemia, 14, 1967–1974.
Kiyono T, Hiraiwa A, Ishii S, Takahashi T and Ishibashi M . (1994). J. Virol., 68, 4656–4661.
Lucas PC, Yonezumi M, Inohara N, McAllister-Lucas LM, Abazeed ME, Chen FF, Yamaoka S, Seto M and Nunez G . (2001). J. Biol. Chem., 276, 19012–19019.
McAllister-Lucas LM, Inohara N, Lucas PC, Ruland J, Benito A, Li Q, Chen S, Chen FF, Yamaoka S, Verma IM, Mak TW and Nunez G . (2001). J. Biol. Chem., 276, 30589–30597.
Morgan JA, Yin Y, Borowsky AD, Kuo F, Nourmand N, Koontz JI, Reynolds C, Soreng L, Griffin CA, Graeme-Cook F, Harris NL, Weisenburger D, Pinkus GS, Fletcher JA and Sklar J . (1999). Cancer Res., 59, 6205–6213.
Motegi M, Yonezumi M, Suzuki H, Suzuki R, Hosokawa Y, Hosaka S, Kodera Y, Morishima Y, Nakamura S and Seto M . (2000). Am. J. Pathol., 156, 807–812.
Ott G, Katzenberger T, Greiner A, Kalla J, Rosenwald A, Heinrich U, Ott MM and Muller-Hermelink HK . (1997). Cancer Res., 57, 3944–3948.
Palacios R and Steinmetz M . (1985). Cell, 41, 727–734.
Remstein ED, James CD and Kurtin PJ . (2000). Am. J. Pathol., 156, 1183–1188.
Roy N, Deveraux QL, Takahashi R, Salvesen GS and Reed JC . (1997). EMBO J., 16, 6914–6925.
Suzuki H, Motegi M, Akagi T, Hosokawa Y and Seto M . (1999). Blood, 94, 3270–3271.
Uren AG, O'Rourke K, Aravind L, Pisabarro MT, Seshagiri S, Koonin EV and Dixit VM . (2000). Mol. Cell., 6, 961–967.
Willis TG, Jadayel DM, Du MQ, Peng H, Perry AR, Abdul-Rauf M, Price H, Karran L, Majekodunmi O, Wlodarska I, Pan L, Crook T, Hamoudi R, Issacson PG and Dyer MJ . (1999). Cell, 96, 35–45.
Yang Y, Fang S, Jensen JP, Weissman AM and Ashwell JD . (2000). Science, 288, 874–877.
Yonezumi M, Suzuki R, Suzuki H, Yoshino T, Oshima K, Hosokawa Y, Asaka M, Morishima Y and Seto M . (2001). Br. J. Haematol., 115, 588–594.
Zhang Q, Siebert R, Yan M, Hinzmann B, Cui X, Xue L, Rakestraw KM, Naeve CW, Beckmann G, Weisenburger DD, Sanger WG, Nowotny H, Vesely M, Callet-Bauchu E, Salles G, Dixit VM, Rosenthal A, Schlegelberger B and Morris SW . (1999). Nat. Genet., 22, 63–68.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Izumiyama, K., Nakagawa, M., Yonezumi, M. et al. Stability and subcellular localization of API2-MALT1 chimeric protein involved in t(11;18) (q21;q21) MALT lymphoma. Oncogene 22, 8085–8092 (2003). https://doi.org/10.1038/sj.onc.1207002
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207002
Keywords
This article is cited by
-
Combined Immunodeficiency Due to MALT1 Mutations, Treated by Hematopoietic Cell Transplantation
Journal of Clinical Immunology (2015)
-
The pathogenesis of MALT lymphomas: where do we stand?
Leukemia (2007)
-
Molecular pathogenesis of MALT lymphoma: two signaling pathways underlying the antiapoptotic effect of API2-MALT1 fusion protein
Leukemia (2006)
-
Malt1
AfCS-Nature Molecule Pages (2006)
-
Helicobacter pylori-negative / API2-MALT1 translocation-negative low-grade MALT lymphoma
Gastric Cancer (2006)